Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 19/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4351760 | 1.00 | TRPV1 (0.55) | TRPV1KDM4EPOLB | |
| SCHEMBL10079879 | 0.87 | TRPV1 (0.46) | TRPV1 | |
| SCHEMBL13893143 | 0.85 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL12398054 | 0.83 | TRPV1 (0.48) | TRPV1 | |
| SCHEMBL1573444 | 0.83 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL4377235 | 0.83 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL472400 | 0.82 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL3699335 | 0.81 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL2363868 | 0.81 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL3410678 | 0.81 | TRPV1 (0.59) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-7615557-B2 | Tetrahydro-naphthalene and urea derivatives | XENTION LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-7615557-B2 | Tetrahydro-naphthalene and urea derivatives | XENTION LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20060258742-A1 | Hydroxy tetrahydro-naphthalenylurea derivatives | BAYER HEAITHCARE AG (DE) | 2006-11-16 | — | — | US | disclosed |
| EP-1678123-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-07-12 | — | — | EP | disclosed |
| EP-1594836-A1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005040100-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2004072020-A1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | HVCN1, NMUR1, OPRL1 | TRPV1 31/4885KDM4E 4585/4885POLB 2847/4885 |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | OPRL1, OPRK1, VAT1 | TRPV1 5/4885KDM4E 4726/4885POLB 2791/4885 |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | NQO2, UGT1A4, CYP4B1 | TRPV1 3997/4885KDM4E 715/4885POLB 713/4885 |
| US-20060258742-A1 | Hydroxy tetrahydro-naphthalenylurea derivatives | NMUR1, HVCN1, GPR17 | TRPV1 18/4885KDM4E 4718/4885POLB 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.